<![CDATA[Background: Epigallocatechin gallate (EGCG) is an antioxidant that has been shown to have various pharmacological activities in both in vivo and in vitro studies. However, EGCG has low oral bioavailability. Alternative routes of administration, such as transdermal, can be used to overcome the stratum corneum of the skin, which provides a barrier that inhibits drugs from entering the dermal microcirculation to prove systemic availability. This limitation can be overcome by applying an elastic nanosized delivery system such as Spanlastic. Objective: To develop a spanlastic gel as an EGCG delivery system for transdermal application. Methods: Sp-EGCG was prepared by injecting ethanol with Tween 60 as the EA and Span 60 as the VB. Design Expert Software was then used to determine the optimum formula to be added to the gel base and tested for ex vivo permeation and in vitro release. Results: Optimization of 13 Sp-EGCG formulas resulted in entrapment efficiencies (79.2925–86.1921) %, zeta potentials (23.86-38.06) -mV, and vesicle sizes (129.933–225.233) nm. The optimal formulation consisted of Span 60 and Tween 80 in a 6:4 ratio and a rotation speed of 1000rpm. The pH value of the Sp-EGCG gel was 5.057 ± 0.016, with a viscosity of 795.43 ± 4.224 cPs and a spreadability of 5.833 ± 0.024 cm. In vitro release results showed that Sp-EGCG provided controlled release following the Higuchi model, while ex vivo permeability test results showed that Sp-EGCG gel increased the amount of EGCG penetration by up to 2.51 times. Conclusion: EGCG was successfully formulated into Sp-EGCG, and F3 was identified as the optimum formula, with a VS of 129.33 nm, ZP of-38.06 mV, and EE of 86.19%. The Sp-EGCG gel increased EGCG permeability in the skin.]]>
Copyrights © 2026
